GSK's darapladib misses in Phase III ACS trial

By BC Staff | May 14, 2014 | 1:30 AM GMT

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said once-daily oral darapladib ( SB-480848) plus standard of care (SOC) missed the primary endpoint

Read the full 195 word article

How to gain access

Continue reading with a
two-week free trial.